1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector [Ajovy] — RxCUI 2287905
RxNorm drug concept · Semantic branded drug
RxCUI 2287905
Semantic branded drug · SBD
● Current RxNorm concept 2 FDA products
4 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2287905
Official name1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector [Ajovy]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as1.5 ML Ajovy 150 MG/ML Auto-Injector; AJOVY 225 MG in 1.5 mL Auto-Injector; Ajovy 225 MG per 1.5 ML Auto-Injector
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)205,598 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Fremanezumab-vfrm Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Ajovy is strictly a preventive medication, not a rescue treatment. You take it on a regular schedule — monthly or quarterly — to reduce how often migraines happen. If you get a mig...
- What exactly does Ajovy do — does it stop a migraine or prevent one?
- Most adults and teens 13 and older can self-inject at home after being trained by their healthcare provider. Your doctor or pharmacist will walk you through the proper technique, i...
- Can I give myself the injection at home, or do I need to go to a clinic?
🕸️ Concept Web — How 1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector [Ajovy]
RxCUI 2287905 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Fremanezumab
2056691IN -
Fremanezumab-vfrm
2056690PIN
-
Fremanezumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Ajovy
2056696BN
-
Ajovy
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Fremanezumab Auto-Injector
2287902SCDF -
Fremanezumab-vfrm Auto-Injector
2648655SCDFP -
Fremanezumab Injectable Product
2056693SCDG -
Fremanezumab-vfrm Injectable Product
2662256SCDGP -
Fremanezumab Auto-Injector [Ajovy]
2287904SBDF -
Fremanezumab-vfrm Auto-Injector [Ajovy]
2655036SBDFP -
Ajovy Injectable Product
2056699SBDG -
Auto-Injector
1649570DF - +1 more in this family
-
Fremanezumab Auto-Injector
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector
2287903SCD -
Fremanezumab-vfrm 150 MG/ML
2056692SCDC -
Fremanezumab-vfrm 150 MG/ML [Ajovy]
2056697SBDC
-
1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
1.5 ML fremanezumab-vfrm 150 MG/ML Auto-Injector
SCD · 2287903 -
Fremanezumab-vfrm 150 MG/ML
SCDC · 2056692 -
Fremanezumab Auto-Injector
SCDF · 2287902 -
Fremanezumab-vfrm Auto-Injector
SCDFP · 2648655 -
Fremanezumab Injectable Product
SCDG · 2056693 -
Fremanezumab-vfrm Injectable Product
SCDGP · 2662256
Brand-Name Concepts
-
Fremanezumab-vfrm 150 MG/ML [Ajovy]
SBDC · 2056697 -
Fremanezumab Auto-Injector [Ajovy]
SBDF · 2287904 -
Fremanezumab-vfrm Auto-Injector [Ajovy]
SBDFP · 2655036 -
Ajovy Injectable Product
SBDG · 2056699 -
Ajovy
BN · 2056696
📦 FDA Products & Package NDCs
2 products · 4 package NDCs
4 package NDCs map to RxCUI 2287905 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 51759-0202-10 | 1 CONTAINER in 1 CARTON (51759-202-10) / 1.5 mL in 1 CONTAI... | AJOVY | Teva Pharmaceuticals USA, Inc. | 2020-03-29 |
| 51759-0202-11 | 1 CONTAINER in 1 CARTON (51759-202-11) / 1.5 mL in 1 CONTAI... | AJOVY | Teva Pharmaceuticals USA, Inc. | 2020-03-29 |
| 51759-0202-22 | 3 CONTAINER in 1 CARTON (51759-202-22) / 1.5 mL in 1 CONTAI... | AJOVY | Teva Pharmaceuticals USA, Inc. | 2020-08-31 |
| 51759-0204-10 | 1 SYRINGE, GLASS in 1 CARTON (51759-204-10) / 1.5 mL in 1 S... | AJOVY | Teva Pharmaceuticals USA, Inc. | 2018-09-15 |
Observed labelers:
Teva Pharmaceuticals USA, Inc. (4)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
💲 Pricing (NADAC)
NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$508.5570
Range $508.3240–$508.6070
· middle 50% $508.4405–$508.5820
· 3 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.